|
|
News Breaks | | | | February 13, 2013 | | 07:36 EDT |  | PLX | Protalix to present new clinical data on ELELYSO at WORLD Symposium
Protalix BioTherapeutics announced that new clinical data on ELELYSO will be presented at the 9th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2013 being held February 13-15 in Orlando, Florida. ELELYSO, the company's first commercial product, is the first FDA-approved plant cell-based enzyme replacement therapy for Gaucher disease. "The data to be presented at the conference further reinforce the use of ELELYSO as a treatment option for Gaucher patients, including naïve Gaucher patients, and patients who were previously treated with imiglucerase," stated Professor Ari Zimran, M.D., Director of the Gaucher Clinic in Shaare Zedek Medical Center, Jerusalem, Israel and lead clinical investigator. A 24 month interim analysis of the switchover trial demonstrates that all patients remained stable with regard to all key disease parameters, spleen volume, liver volume, platelet count and hemoglobin concentration, as well as the chitotriosidase activity biomarker after switching to ELELYSO from imiglucerase. The safety analysis presented for the 24-month switchover treatment duration demonstrates that ELELYSO was well tolerated, and no drug related serious adverse events were reported. | |
|
News For PLX From The Last 14 Days Check below for free stories on PLX the last two weeks. |
|
|
| May 16, 2013 | | 11:15 EDT |  | PLX | High option volume stocks: HMY MOLX PLX DSW EGLE
 Subscribe for More Information | |
|
|
|
|
|
|
